Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

1. Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC)

Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC) Published 13 April 2020 1 SMC2242 naldemedine 200 micrograms film-coated tablets (Rizmoic®) Shionogi BV 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission naldemedine (Rizmoic ® ) is accepted (...) for use within NHSScotland. Indication under review: For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the treatment of opioid induced constipation (OIC) in adult

2020 Scottish Medicines Consortium

2. Lactitol (Pizensy) - To treat chronic idiopathic constipation (CIC) in adults

Lactitol (Pizensy) - To treat chronic idiopathic constipation (CIC) in adults Drug Approval Package: PIZENSY PIZENSY " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: PIZENSY Company: Braintree Laboratories, Inc. Application Number: 211281 Approval Date: 02/12/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

3. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Gastroenterol Actions , 115 (2), 281-293 Feb 2020 Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) , , Affiliations Expand Affiliations 1 Division

2020 EvidenceUpdates

4. Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults

Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

6. A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation Full Text available with Trip Pro

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol (PEG) 3350 in patients receiving opioids for noncancer pain.This crossover study included two 2-week active treatment periods, each preceded by a 1-week washout period (NCT03060512). Individuals with baseline

2019 EvidenceUpdates

7. Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines

Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/21684/2019 EMEA/H/C/004256 Rizmoic An overview of Rizmoic and why it is authorised in the EU (...) What is Rizmoic and what is it used for? Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements). It contains the active substance naldemedine. How is Rizmoic used? Rizmoic is available as 200 microgram tablets. The recommended dose is one tablet once daily, which the patient can take with or without a laxative. The patient must stop taking Rizmoic when

2019 European Medicines Agency - EPARs

8. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation Full Text available with Trip Pro

American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 156, Issue 1, Pages 218–226 American Gastroenterological Association Institute Guideline on the Medical Management of Opioid (...) -Induced Constipation x Seth D. Crockett Affiliations Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina Correspondence Reprint requests Address requests for reprints to: Seth D. Crockett, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina, CB 7080, 130 Mason Farm Road, Chapel Hill, North Carolina 27599. fax: (919) 966-8929. 1 , ∗ , x Seth D. Crockett Affiliations Division of Gastroenterology

2019 American Gastroenterological Association Institute

9. Constipation in children

Constipation in children Constipation in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation in children Last reviewed: February 2019 Last updated: February 2019 Summary Childhood constipation is typically characterised by infrequent bowel evacuations, large stools, and difficult or painful defecation. Symptoms may result from low fibre, poor nutrient, and/or insufficient water intake, which leads (...) to excessive hardening of the stool. This often starts as an acute problem but can progress to faecal impaction and chronic constipation. Particularly in young children, any cause of painful defecation may provoke active withholding. Withholding may worsen the constipation and lead to a vicious cycle. Duration of constipation and amount of stool burden may depend on capacity of the child's rectum, the degree of megarectum, and other factors including rectal sensory function. After faecal disimpaction

2019 BMJ Best Practice

10. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain Full Text available with Trip Pro

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain Oral methylnaltrexone was shown to be effective in treating opioid-induced constipation (OIC) in patients with chronic noncancer pain in a Phase III randomized controlled trial. This report provides a detailed safety analysis from that study.Adults (n=803) with chronic noncancer pain for ≥2 months and confirmed OIC while receiving opioid doses ≥50 mg morphine equivalent per day for ≥14 days

2019 EvidenceUpdates

11. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. Full Text available with Trip Pro

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. This post hoc, pooled, subgroup analysis of two randomised studies evaluated baseline characteristics that may influence the efficacy and safety of naldemedine in patients with opioid-induced constipation (OIC) and cancer.Data for patients who received 0.2 mg naldemedine or placebo were pooled from randomised, placebo-controlled, phase IIb

2019 ESMO open Controlled trial quality: uncertain

12. Baseline severe constipation negatively impacts functional outcomes of surgery for deep endometriosis infiltrating the rectum: Results of the ENDORE randomized trial. (Abstract)

Baseline severe constipation negatively impacts functional outcomes of surgery for deep endometriosis infiltrating the rectum: Results of the ENDORE randomized trial. Predictive factors of functional outcomes after the surgery of rectal endometriosis are not well identified. Our recent randomized trial did not find significant differences between functional outcomes in patients managed by radical or conservative rectal surgery.To identify preoperative factors which determine functional outcomes (...) of surgery in patients with rectal endometriosis.We performed a cohort study on the population of a 2-arm randomised trial, from March 2011 to August 2013. Patients were enrolled in three French university hospitals and had either conservative surgery by shaving or disc excision, or radical rectal surgery by segmental resection. The primary endpoint was the proportion of patients experiencing one of the following symptoms: constipation, frequent bowel movements, anal incontinence, dysuria or bladder

2019 Journal of gynecology obstetrics and human reproduction Controlled trial quality: predicted high

13. Prucalopride (Motegrity) - To treat chronic idiopathic constipation

Prucalopride (Motegrity) - To treat chronic idiopathic constipation Drug Approval Package: Motegrity (prucalopride) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Motegrity (prucalopride) Company: Shire Development LLC Application Number: 210166 Approval Date: 12/14/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

14. Constipation

Constipation Constipation - NICE CKS Share Constipation: Summary Constipation is a symptom-based disorder which describes defecation that is unsatisfactory because of infrequent stools, difficulty passing stools, or the sensation of incomplete emptying. The Rome IV diagnostic criteria for constipation include spontaneous bowel movements occurring less than three times a week. Chronic constipation usually describes symptoms which are present for at least 12 weeks in the preceding six months (...) . Faecal loading/impaction describes retention of faeces to the extent that spontaneous evacuation is unlikely. Functional (primary or idiopathic)constipation is chronic constipation without a known cause. Secondary (organic) constipation is constipation caused by a drug or underlying medical condition. Constipation may occur at any age but is more common in women, the elderly, and during pregnancy. Assessment of a person with constipation should include: Any red flag symptoms or signs that may suggest

2019 NICE Clinical Knowledge Summaries

15. Constipation in children

Constipation in children Constipation in children - NICE CKS Share Constipation in children: Summary Constipation is a decrease in the frequency of bowel movements characterized by the passing of hardened stools which may be large and associated with straining and pain. Normal stool frequency in children ranges from an average of 4 per day in the first week of life to 2 per day at 1 year of age. Passing between 3 stools per day and 3 per week is usually attained by 4 years of age. Constipation (...) is termed idiopathic (functional) if it cannot be explained by any anatomical or physiological abnormality. Contributing factors for constipation include pain, fever, inadequate fluid intake, reduced dietary fibre intake, toilet training issues, the effects of drugs, psychosocial issues, and a family history of constipation. Two or more of the following clinical features indicate that a child is constipated: Fewer than three complete stools per week (unless exclusively breastfed, when stools may

2019 NICE Clinical Knowledge Summaries

16. Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines

Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines † P. J. Larkin 1,2 , N. I. Cherny 3 , D. La Carpia 4 , M. Guglielmo 5 , C. Ostgathe 6 , F. Scotte ´ 7 & C. I. Ripamonti 5 ,on behalf of the ESMO Guidelines Committee * 1 School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin; 2 (...) Department of Medical Oncology and Supportive Care, Foch Hospital, Suresnes, France *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: March 2018. Introduction Constipation is a common problem in patients with advanced can- cer and a signi?cant source of major morbidity and distress, which is often under-appreciated [1]. Constipation is subjectively experi- enced

2018 European Society for Medical Oncology

17. Constipation

Constipation Constipation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation Last reviewed: February 2019 Last updated: October 2018 Summary A detailed history and physical examination, including a digital rectal examination, is the first step in the evaluation of constipation. Diagnostic evaluation may include a colonoscopy if indicated, colonic transit study, anorectal manometry, and a balloon expulsion (...) study. Initial treatment consists of lifestyle modification and laxatives. Medical treatment should be tailored to the underlying aetiology. Patients who do not respond to medical treatment may need specialised evaluation for pelvic floor dysfunction and biofeedback therapy. Surgery is only rarely indicated. Definition Chronic constipation is a polysymptomatic heterogeneous disorder. Patients define constipation on the basis of excessive straining, a sense of incomplete evacuation, failed or lengthy

2018 BMJ Best Practice

18. Constipation

Constipation Top results for constipation - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for constipation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

19. Constipation

Constipation Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

20. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials (Abstract)

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end (...) across both studies. All secondary end points (stool frequency/consistency, straining, abdominal symptoms) showed statistically significant improvements compared with placebo. The most common AE was diarrhea (3 mg, 4.3%; 6 mg, 4.0%; placebo, 1.0%). Discontinuation due to diarrhea was infrequent (3 mg, 1.2%; 6 mg, 1.4%; placebo, 0).Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability.

2018 EvidenceUpdates